Colon cancer

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
5 Unique sponsors
9 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 4
— ATC code not specified 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Antimetabolite 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Phase III: 2 Phase II: 3

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

2 trials
  • Centre Hospitalier Universitaire De Dijon Academic
    BEVACIZUMAB; TRIFLURIDINE, TIPIRACIL
    2023-505046-26-00 1 country 2026 n=249
    Recruiting
  • Centre Hospitalier Universitaire Rouen Academic
    CAPECITABINE; FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN
    2024-516456-17-00 1 country 2024 n=232
    Recruiting

Phase II

3 trials
  • ASST Grande Ospedale Metropolitano Niguarda Academic
    IPILIMUMAB; NIVOLUMAB
    2022-502524-41-00 1 country 2023 n=24
    Ended
  • Institute Of Oncology Ljubljana Academic
    IMP not specified
    2025-521808-22-01 1 country n=100
    Pending
  • UZ Leuven Academic
    DOSTARLIMAB
    2024-512499-36-00 1 country 2025 n=10
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
ASST Grande Ospedale Metropolitano Niguarda Academic 1 Phase II 0
Institute Of Oncology Ljubljana Academic 1 Phase II 0
UZ Leuven Academic 1 Phase II 1
Centre Hospitalier Universitaire De Dijon Academic 1 Phase III 1
Centre Hospitalier Universitaire Rouen Academic 1 Phase III 1
New trials by year
2023
1
2024
1
2025
1
2026
1
← All indication landscapes